Influence of Liver Disease and Environmental Factors on Hepatic Monooxygenase Activity in Vitro

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 1981 Jan 1

PMID 7308271

Citations 17

Authors

M J Brodie

A R Boobis

C J Bulpitt

D S Davies

Affiliations

Soon will be listed here.

Abstract

The effects of liver disease and environmental factors on hepatic microsomal cytochrome P-450 content, NADPH-cytochrome c reductase (reductase) activity and aryl hydrocarbon hydroxylase (AHH) activity have been simultaneously investigated in 70 patients undergoing diagnostic liver biopsy. The activity of reductase was not significantly affected by the presence of liver disease or any of the environmental factors studied. Cytochrome P-450 content decreased with increasing severity of liver disease whereas AHH activity was only significantly reduced in biopsies showing hepatocellular destruction. None of the parameters of monooxygenase activity varied significantly with the age or sex of the patients. Alcohol excess was associated with decreased cytochrome P-450 content and AHH activity and this effect was independent of the histological status of the biopsy. Both high caffeine intake and cigarette smoking increased AHH activity in the absence of any change in cytochrome P-450 content. There was a positive correlation between the number of meat meals eaten per week and cytochrome P-450 content. Chronic treatment with enzyme-inducing anticonvulsants appeared to increase both cytochrome P-450 content and AHH activity. Despite differential effects of liver disease and environmental influences on cytochrome P-450 content and AHH activity there was a highly significant correlation between the two parameters. The results of the present study correlate well with the known effects of disease and environment on drug metabolism in vivo.

Citing Articles

Role of CYP4F2 as a novel biomarker regulating malignant phenotypes of liver cancer cells via the Nrf2 signaling axis.

Wan S, Pan Q, Yang G, Kuang J, Luo S Oncol Lett. 2020; 20(4):13.

PMID: 32774486 PMC: 7405372. DOI: 10.3892/ol.2020.11874.

Liver function and phase I drug metabolism in the elderly: a paradox.

Schmucker D Drugs Aging. 2002; 18(11):837-51.

PMID: 11772124 DOI: 10.2165/00002512-200118110-00005.

The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Le Couteur D, McLean A Clin Pharmacokinet. 1998; 34(5):359-73.

PMID: 9592620 DOI: 10.2165/00003088-199834050-00003.

Lidocaine metabolite formation as a measure of perioperative liver function.

SHIMANUKI K, Sakurabayashi I, Miyata M, Kiyozaki H, Suzuki W, Kashii A Surg Today. 1993; 23(4):315-9.

PMID: 8318785 DOI: 10.1007/BF00309048.

Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice.

McPherson G, Benjamin I, Boobis A, Brodie M, Hampden C, Blumgart L Gut. 1982; 23(9):734-8.

PMID: 7106619 PMC: 1419759. DOI: 10.1136/gut.23.9.734.

References

Brodie M, Boobis A, Toverud E, Ellis W, Murray S, Dollery C . Drug metabolism in white vegetarians. Br J Clin Pharmacol. 1980; 9(5):523-5. PMC: 1429941. DOI: 10.1111/j.1365-2125.1980.tb05853.x. View

Davies D, Thorgeirsson S . Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man. Ann N Y Acad Sci. 1971; 179:411-20. DOI: 10.1111/j.1749-6632.1971.tb46918.x. View

Homeida M, Karrar Z, Roberts C . Drug metabolism in malnourished children: a study with antipyrine. Arch Dis Child. 1979; 54(4):299-302. PMC: 1545296. DOI: 10.1136/adc.54.4.299. View

Vesell E . The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979; 26(3):275-86. DOI: 10.1002/cpt1979263275. View

Hunt S, Jusko W, Yurchak A . Effect of smoking on theophylline disposition. Clin Pharmacol Ther. 1976; 19(5 Pt 1):546-51. DOI: 10.1002/cpt1976195part1546. View

Wilkinson G, Schenker S . Drug disposition and liver disease. Drug Metab Rev. 1975; 4(2):139-75. DOI: 10.3109/03602537508993754. View

Kapitulnik J, Popper P, Conney A . Comparative metabolism of benzo[a]pyrene and drugs in human liver. Clin Pharmacol Ther. 1977; 21(2):166-76. DOI: 10.1002/cpt1977212166. View

Wilmana P, Brodie M, Mucklow J, Fraser H, Toverud E, Davies D . Reduction of circulating 25-hydroxyvitamin D by antipyrine. Br J Clin Pharmacol. 1979; 8(6):523-8. PMC: 1429906. DOI: 10.1111/j.1365-2125.1979.tb01039.x. View

Atlas S, Vesell E, Nebert D . Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. Cancer Res. 1976; 36(12):4619-30. View

10.

Hoensch H, Hartmann F, Schomerus H, BIECK P, Dolle W . Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage. Gut. 1979; 20(8):666-72. PMC: 1412535. DOI: 10.1136/gut.20.8.666. View

11.

Sotaniemi E, Pelkonen R, Ahokas J, Pirttiaho H, Ahlqvist J . Drug metabolism in epileptics: in vivo and in vitro correlations. Br J Clin Pharmacol. 1978; 5(1):71-6. PMC: 1429229. DOI: 10.1111/j.1365-2125.1978.tb01600.x. View

12.

Fraser H, Williams F, Davies D, Draffan G, Davies D . Amylobarbitone hydroxylation kinetics in small samples of rat and human liver. Xenobiotica. 1976; 6(8):465-72. DOI: 10.3109/00498257609151659. View

13.

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

14.

Kalamegham R, Krishnaswamy K, Krishnamurthy S, Bhargava R . Metabolism of drugs and carcinogens in man: antipyrine elimination as an indicator. Clin Pharmacol Ther. 1979; 25(1):67-73. DOI: 10.1002/cpt197925167. View

15.

Fraser H, Mucklow J, Bulpitt C, Khan C, Mould G, Dollery C . Environmental effects on antipyrine half-life in man. Clin Pharmacol Ther. 1977; 22(5 Pt 2):799-808. DOI: 10.1002/cpt1977225part2799. View

16.

Farrell G, Cooksley W, Powell L . Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther. 1979; 26(4):483-92. DOI: 10.1002/cpt1979264483. View

17.

DARBY F, Grundy R . The metabolism of (ureyl-14C)tolbutamide in vitro and in vivo in man. Life Sci. 1973; 13(2):97-105. DOI: 10.1016/0024-3205(73)90184-7. View

18.

Dollery C, Fraser H, Mucklow J, Bulpitt C . Contribution of environmental factors to variability in human drug metabolism. Drug Metab Rev. 1979; 9(2):207-20. DOI: 10.3109/03602537908993891. View

19.

Matsubara T, Baron J, Peterson L, Peterson J . NADPH-cytochrome P450 reductase. Arch Biochem Biophys. 1976; 172(2):463-9. DOI: 10.1016/0003-9861(76)90099-0. View

20.

Black M, Perrett R, Carter A . Hepatic bilirubin UDP-glucuronyl transferase activity and cytochrome P450 content in a surgical population, and the effects of preoperative drug therapy. J Lab Clin Med. 1973; 81(5):704-12. View